Download PDF
Thromb Haemost 1988; 60(02): 137-140
DOI: 10.1055/s-0038-1647017
Original Article
Schattauer GmbH Stuttgart

Plasma and Urinary Heparin Cofactor II Levels in Patients with Nephrotic Syndrome

E Grau
*   The Servei d’Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
,
A Oliver
*   The Servei d’Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
,
J Félez
*   The Servei d’Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
,
P Barceló
**   Institut d’Urologia, Nefrologia i Andrologia (Fundació Puigvert), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
,
C Fernandez
**   Institut d’Urologia, Nefrologia i Andrologia (Fundació Puigvert), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
,
J A Ballarin
**   Institut d’Urologia, Nefrologia i Andrologia (Fundació Puigvert), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
,
J Fontcuberta
*   The Servei d’Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
,
M L I Rutilant
*   The Servei d’Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
› Author Affiliations
Further Information

Publication History

Received 29 May 1986

Accepted after revision 31 March 1988

Publication Date:
28 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Heparin cofactor II (HC II) levels were measured by electroimmunoassay in plasmas and urines from 68 patients with nephrotic syndrome. In addition, antithrombin III (AT III) and protein C (PC) activities and antigens were measured also in the same group of patients. Seven of these patients had histories of thrombosis. Plasma HC II levels (mean ± SD 105 ± 43) were not different from levels in healthy subjects (94 ± 17). Only 5 patients had low plasma levels of HC II. None of the patients with thrombosis had low HC II levels. Even though measurable amounts of HC II were found in 25 urines from 50 patients. There was a relationship in the urinary excretion between HC II and AT III and their urinary clearances were quite similar. However, no correlation was found between plasma HC II and AT III levels, and levels of AT III activity and antigen were significantly lower than in healthy subjects. Three patients with hystories of thrombosis had low AT III levels. Most patients (including those with thrombosis histories) had high plasma PC levels and increased urinary loss.

It is suggested that HC II does not play an important role in the pathogenesis of thrombosis in nephrotic syndrome.

Keywords

Heparin cofactor II - Antithrombin III - Protein C - Nephrotic syndrome
 

  • References

  • 1 Llach F. Hypercoagulability, renal vein thrombosis and other thrombotic complications of nephrotic syndrome. Kidney Int. 1985; 28: 429-439
    CrossrefPubMedGoogle Scholar
  • 2 Kauffmann RH, Veltkamp JJ, Van Tilburg NH, Van Es LA. Acquired antithrombin deficiency and thrombosis in nephrotic syndrome. Am J Med 1978; 65: 607-613
    CrossrefPubMedGoogle Scholar
  • 3 Vaziri ND, Paule P, Toohey J, Hung E, Shahriar A, Riad D, Pahl MV. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Intern Med 1984; 144: 1802-1803
    CrossrefPubMedGoogle Scholar
  • 4 Boneu B, Boissou F, Abbal M, Sie P, Caranobe C, Barthe P. Comparison of progressive antithrombin activity and concentration of three thrombin inhibitors in nephrotic syndrome. Thromb Haemostas 1981; 46: 623-625
    PubMedGoogle Scholar
  • 5 Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
    CrossrefPubMedGoogle Scholar
  • 6 Tran TH, Lammle B, Zbinden B, Duckert F. Heparin cofactor II: purification and antibody production. Thromb Haemostas 1986; 55: 19-23
    PubMedGoogle Scholar
  • 7 Birginshaw GF, Shanberge JN. Identification of two distinct heparin cofactors in human plasma: II. Inhibition of thrombin and activated factor X. Thromb Res 1974; 4: 463-477
    CrossrefPubMedGoogle Scholar
  • 8 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169
    PubMedGoogle Scholar
  • 9 Yamagishi R, Niwa M, Kondo S, Sakuragawa N, Koide T. Purification and biological property of heparin cofactor II: activation of heparin cofactor II and antithrombin III by dextran sulfate and various glycosaminoglycans. Thromb Res 1984; 36: 633-642
    CrossrefPubMedGoogle Scholar
  • 10 Sie P, Dupouy D, Pichon J, Boneu P. Constitutional heparin cofactor II deficiency associated to recurrent venous thrombosis. Lancet 1985; II: 414-416
    PubMedGoogle Scholar
  • 11 Tran TH, Marbet GA, Duckert F. Association of hereditary heparin cofactor II deficiency with thrombosis. Lancet 1985; II: 413-414
    PubMedGoogle Scholar
  • 12 Sala N, Owen WG, Collen D. A functional assay of protein C in human plasma. Blood 1984; 63: 671-675
    PubMedGoogle Scholar
  • 13 Griffith MJ, Noyes CM, Church FC. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 1985; 260: 2218-2225
    PubMedGoogle Scholar
  • 14 Sié P, Dupouy D, Pichon J, Boneu B. Turnover study of heparin cofactor II in healthy man. Thromb Haemostas 1985; 54: 635-638
    PubMedGoogle Scholar
  • 15 Girot RF, Jaubert F, Leon M, Bellon B, Aiach M, Josso F, Lepelletier O, Beguin S, Monnet JP. Albumin, fibrinogen, prothrombin and antithrombin III variations in blood, urines and liver in rat nephrotic syndrome. Thromb Haemostas 1983; 49: 13-17
    PubMedGoogle Scholar
  • 16 Mannucci PM, Valsecchi C, Bottasso B, D’Angelo A, Casati S, Ponticelli C. High plasma levels of protein C activity and antigen in the nephrotic syndrome. Thromb Haemostas 1986; 55: 31-33
    PubMedGoogle Scholar